AHS 2018

Greater Occipital Nerve Block Effective for Acute Relief of Refractory Migraine

Greater Occipital Nerve Block Effective for Acute Relief of Refractory Migraine

By

The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

By

Eptinezumab has shown 100% bioavailability when administered intravenously.

Fremanezumab May Help Reduce Medication Overuse in Chronic Migraine

Fremanezumab May Help Reduce Medication Overuse in Chronic Migraine

By

Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.

Ubrogepant Reduces Acute Migraine Pain, Symptoms

Ubrogepant Reduces Acute Migraine Pain, Symptoms

By

Results from the ACHIEVE II study were presented at the American Headache Society's 60th Annual Scientific Meeting.

Rapid Treatment Onset, Reduced Headache Days With Galcanezumab

Rapid Treatment Onset, Reduced Headache Days With Galcanezumab

By

In the post-hoc analysis, researchers evaluated the time to onset of effect of galcanezumab as well as whether treatment with the study drug was associated with a reduction in migraine headache days.

Poll: Should Migraineurs Avoid Headache Triggers?

Poll: Should Migraineurs Avoid Headache Triggers?

By

Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.

Chronic Migraine Associated With Age-Related Changes in Cortical Thickness

Chronic Migraine Associated With Age-Related Changes in Cortical Thickness

By

Individuals with chronic migraine may present with age-related changes in cortical thickness.

Posttraumatic Headaches More Severe, Frequent Than Nontraumatic Headaches

Posttraumatic Headaches More Severe, Frequent Than Nontraumatic Headaches

By

The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.

Novel Oral Treatment Safe, Effective for Migraine Headache Relief

Novel Oral Treatment Safe, Effective for Migraine Headache Relief

By

The 2 randomized, phase 3, double-blind studies included in this presentation were the SAMURAI and SPARTAN trials.

Erenumab Remains Safe, Tolerable Over 3-Plus Years of Treatment in Episodic Migraine

Erenumab Remains Safe, Tolerable Over 3-Plus Years of Treatment in Episodic Migraine

By

In their interim analysis of a 5-year open-label extension trial, study investigators evaluated the safety and tolerability of erenumab treatment in episodic migraine patients who completed ≥3 years of the trial or discontinued treatment.

Chronic Migraine Burden Has Significant Impact on Relationships, Family Life

Chronic Migraine Burden Has Significant Impact on Relationships, Family Life

By

The CaMEO study is a prospective, longitudinal web-based survey designed to characterize the impact of migraine on aspects of quality of life.

Adverse Childhood Events Associated With Medication Overuse Headache

Adverse Childhood Events Associated With Medication Overuse Headache

By

Known risk factors for medication overuse headache include smoking, anxiety, family history of substance abuse, migraine history, depression, and obsessive-compulsive disorder.

Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment

Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment

By

A phase 3 study examined a low-dose subcutaneous autoinjection of sumatriptan in the acute treatment of migraines with or without aura in adults.

Cardiovascular, Psychiatric Comorbidity Patterns Evident in Migraine

Cardiovascular, Psychiatric Comorbidity Patterns Evident in Migraine

By

The comorbidities commonly reported in patients with migraine include those involving cardiovascular, psychiatric, pain, and respiratory conditions, the researchers reported.

Rimegepant Shows Efficacy and Safety in Treating Acute Migraine

Rimegepant Shows Efficacy and Safety in Treating Acute Migraine

By

Rimegepant is a safe and efficacious pharmacological treatment of acute migraine in adults.

Fremanezumab Effective in Reversion of Chronic Migraine to Episodic Migraine

Fremanezumab Effective in Reversion of Chronic Migraine to Episodic Migraine

By

This Phase III, multicenter, double-blind study sought to explore the effect of fremanezumab on the potential reversion from chronic migraine to episodic migraine.

Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine

Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine

By

Patients with difficult-to-treat migraine were randomly assigned 1:1 to either 140 mg erenumab or placebo.

OnabotulinumtoxinA Safer, More Effective for Headache Prevention Than Topiramate

OnabotulinumtoxinA Safer, More Effective for Headache Prevention Than Topiramate

By

This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.

Intravenous Eptinezumab Effectively Reduces Monthly Migraine Days

Intravenous Eptinezumab Effectively Reduces Monthly Migraine Days

By

More patients in the 100 mg and 300 mg eptinezumab groups achieved a 100% reduction in monthly migraine days over the 12 weeks compared with placebo.

Menopause Transition Often Prompts Changes in Migraine Pattern, Characteristics

Menopause Transition Often Prompts Changes in Migraine Pattern, Characteristics

By

This retrospective study sought to assess migraine patterns in 69 menopausal women between ages 40 and 60 who were treated at Partners Healthcare Hospitals for concurrent migraine headache.

Headache Calendar Helps Patients Track Relationship Between Headache, Triggers

Headache Calendar Helps Patients Track Relationship Between Headache, Triggers

By

This cross-sectional, observational study sought to evaluate the accuracy of individuals with headache to appraise the relationship between potential trigger factors and headache events.

Fremanezumab Reduces Monthly Migraine Days in Chronic Migraine

Fremanezumab Reduces Monthly Migraine Days in Chronic Migraine

By

Fremanezumab has shown efficacy in safely reducing monthly headache days in individuals with chronic migraine.

Sign Up for Free e-newsletters



CME Focus